Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E9PK
|
||||
| Former ID |
DNC004144
|
||||
| Drug Name |
MOXONIDINE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Alcohol use disorders [ICD9: 303; ICD10:F10.2] | Approved | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C9H15Cl2N5O2
|
||||
| Canonical SMILES |
CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC
|
||||
| InChI |
1S/C9H12ClN5O/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9/h3-4H2,1-2H3,(H2,11,12,15)
|
||||
| InChIKey |
WPNJAUFVNXKLIM-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 75438-57-2
|
||||
| PubChem Compound ID | |||||
| SuperDrug ATC ID |
C02AC05
|
||||
| Target and Pathway | |||||
| Target(s) | Alpha-2A adrenergic receptor | Target Info | Inhibitor | [2] | |
| Alpha-2C adrenergic receptor | Target Info | Inhibitor | [2] | ||
| Alpha-2B adrenergic receptor | Target Info | Inhibitor | [2] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP00002:Alpha adrenergic receptor signaling pathway | |||||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Reactome | Adrenoceptors | ||||
| Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
| Adrenaline,noradrenaline inhibits insulin secretion | |||||
| G alpha (i) signalling events | |||||
| G alpha (z) signalling events | |||||
| Surfactant metabolismR-HSA-390696:Adrenoceptors | |||||
| WikiPathways | Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Platelet Aggregation (Plug Formation) | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP58:Monoamine GPCRs | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. J Pharmacol Exp Ther.2003 Aug;306(2):646-57. Epub 2003 May 19. | ||||
| REF 2 | J Med Chem. 1996 Mar 15;39(6):1193-5.Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.